Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

An extensive Phase 3 clinical trial programme

  • ADULTS:
    DUPIXENT was studied in six Phase 3 clinical trials, in adults with moderate-to-severe atopic dermatitis (AD) including more than 2,400 adult patients worldwide, both as a monotherapy and with TCS for up to 52 weeks1
  • ADOLESCENTS:
    DUPIXENT was studied as a monotherapy, in 251 adolescents with moderate-to-severe AD inadequately controlled with topical treatment for up to 16 weeks2,3

AD, atopic dermatitis.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: December 2020.
  2. Paller A, et al. Dupilumab for Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 3, Randomized, Double-Blinded Trial (Poster 10051) presented at the 77th annual meeting of the American Academy of Dermatology, Washington, DC, USA, March 1–5 2019.
  3. Simpson EL, et al. Dupilumab Efficacy and Safety in Adolescents With Moderate-to-Severe Atopic Dermatitis: Results From a Multicenter, Randomized, Placebo Controlled, Double-Blind, Parallel-Group, Phase 3 Study (Poster PA-17) presented at the 43rd annual Hawaii Dermatology Seminar; Waikoloa, HI, USA, February 17–22 2019.